Skip to main content
Article
Clostridium difficile in inflammatory bowel disease: a retrospective study
Gastroenterology Research and Practice
  • William Gillespie
  • Neil Marya
  • Julien Fahed, Advocate Aurora Health
  • Gregory Leslie
  • Krunal Patel
  • David R Cave
Affiliations

Department of Gastroenterology, Aurora Healthcare

Publication Date
10-4-2017
Abstract

Aim: To investigate the epidemiology and risk factors of Clostridium difficile infections (CDI) in patients with inflammatory bowel disease (IBD).

Methods: This is a retrospective study of patients diagnosed with IBD. 1006 charts were screened and 654 patients met the inclusion criteria. Patients were divided into 2 cohorts based on the presence of prior diagnosis of CDI. Statistical analysis with Pearson's chi-squared and two-sample t-test was performed.

Results: The incidence of CDI among IBD patients was 6.7%. There was equal prevalence of CDI among Crohn's disease (CD) (n = 21, 49%) and ulcerative colitis (UC) (n = 22, 51%). IBD patients acquired CDI at a mean age of 42.7 years, with 56% of infections acquired in the community and only 28% associated with healthcare. Only 30% of IBD patients with CDI had prior antibiotic use, and 16% had prior steroid use. IBD patients were significantly more likely to require biologic therapy (57% versus 37%, p < 0.01) and have extraintestinal manifestations of IBD (43% versus 28%, p < 0.02).

Conclusions: IBD patients are more susceptible to CDI at a younger age and often lack traditional risk factors. IBD patients with at least one CDI were more likely to require biologic therapy and had greater rates of extraintestinal manifestations.

Document Type
Article
PubMed ID
29109735
Citation Information

Gillespie W, Marya N, Fahed J, Leslie G, Patel K, Cave DR. Clostridium difficile in inflammatory bowel disease: a retrospective study. Gastroenterol Res Pract. 2017;2017:4803262. doi: 10.1155/2017/4803262